der(5)t(1;5)(q12-q25;q13-q35)

2016-02-01 Soad Al Bahar , Adriana Zamecnikova Affiliation

1.Kuwait Cancer Control Center, Department of Hematology, Laboratory of Cancer Genetics, Kuwait; annaadria@yahoo.com

Abstract

Review on t(1;5)(q12-q25;q13-q35), with data on clinics.

Clinics and Pathology

Disease

Myeloid malignancies, acute lymphoblastic leukemia (ALL) multiple myeloma (MM), B- and T- cell lymphoma and sporadic cases of other malignancies.

Phenotype stem cell origin

Myeloid malignancies in 10 patients: 1 chronic myeloid leukemia (CML) (Dastugue et al., 1986), 3 myelodysplastic syndromes (MDS) (Furuya et al., 1992; Johansson et al., 1997; Quentin et al., 2011) and 6 acute myeloid leukemia (AML) cases (Gyger et al., 1989; Shikano et al., 1993; Wong et al., 1993; Borkhardt et al., 2000; Van Limbergen et al., 2002; Jekarl et al., 2010).
Acute lymphoblastic leukemia in 8 cases (Saikevych et al., 1991; Martin et al., 1996; Rieder et al., 1996; van den Berghe et al., 2000; Chang et al., 2006; Wehrli et al., 2009; Paulsson et al ., 2015; Safavi et al., 2015).
Multiple myeloma in 11 cases (Smadja et al., 2001; Smadja et al., 2003. Nilsson et al., 2002; Mohamed et al., 2007; Lim et al., 2013; Sawyer et al., 2014). B-cell neoplasms: follicular lymphoma in 3 (Le Baccon et al., 2001; Horsman et al., 2003; Johnson et al., 2008), diffuse large B-cell lymphoma in 4 (Jonveaux et al., 1990; Jerkeman et al., 1999; Yoshioka et al., 2005; Ruminy et al., 2006) and mature B-cell neoplasm (Tanaka et al., 2001) in 1 patient. T-cell neoplasms: reported in one case each of peripheral T-cell lymphoma (Schlegelberger et al., 1994), hepatosplenic T-cell lymphoma (Ott et al.,1998), and mycosis fungoides/Sezary syndrome (Perez-Vila et al., 2000).
Table 1. Reported cases with unbalanced chromosome translocations der(5)t(1;5) involving 1q12-q25 and 5q13-q35.

	Sex/ Age	Disease	Karyotype
		Myeloid malignancies
1	F/68	CML (biphenotypic blast phase)	46,XX,der(5)t(1;5)(q23;q32),t(9;22)(q34;q11),t(14;14)(q11;q32)
2	M/57	AML-M1	43,XY,-1,del(5)(q13q33),der(5)t(1;5)(q23;q33),-7,add(8)(p23),del(11)(p15),add(12)(p11),-14,-16,-17,+2mar
3	M/76	MDS	46,XY,der(5)t(1;5)(q21;q35)/46,XY,+der(1)t(1;7)(p11;p11),-7
4	F/0
5	M/13	AML-M1	49,XX,+3,+der(5)t(1;5)(q21;q21),+22
6	M/64	MDS (Hodgkin disease, radiotherapy, chemotherapy)	46,XY,der(5)t(1;5)(q24;q14)
7	M/6	AML	46,XY,der(1)add(1)(p36)add(1)(q32),der(5)t(1;5)(q25;q22),add(6)(q15),del(7)(p14p15),del(17)(p12)
8	M/76	AML-M2	45,XY,der(1)t(1;5)(q21;q33),der(3)t(3;6)(q21;q22),der(?3)r(3;6),der(5)t(1;5)(q21;q13),-18
9	F/21	AML-M1	46,XX,der(5)t(1;5)(q12;q35),t(16;21)(p11;q22)/46,idem,t(1;7)(p32;p22)/46,idem,del(6)(q23)/48,XX,+7,+8,t(16;21)
10	M/5	MDS (Fanconi anemia)	46,XY,der(5)t(1;5)(q12;q14)
		Acute lymphoblastic leukemia
11	F/70	BAL	46,XX,t(9;22)(q34;q11)/46,idem,der(5)t(1;5)(q22;q35)/46,idem,der(6)t(1;6)(q22;q27)
12	M	ALL	59,XXY,+Y,-1,-2,-3,der(5)t(1;5)(q21;q21),-7,-9,-11,-12,-13,-16,-19,-20,+21,-22
13	M/57	B-ALL	48,XY,der(5)t(1;5)(q12-21;q35),+8,-9,t(9;22)(q34;q11),+14,+der(22)t(9;22)
14	M	ALL	58,XXY,-1,-2,-3,der(5)t(1;5)(q23;q31),-7,-8,-9,+10,-11,-12,-13,-15,-16,+18,-19,-20
15	M/4	ALL	51-55,XY,+der(5)t(1;5)(q12;q31),+6,+10,+18,+18,+21,+21
16	M/9	ALL	47,X,-Y,+der(5)t(1;5)(q21;q31),-8,del(9)(p13),+13,+mar
17	M/2	ALL	62,XY,+X,+Y,+der(5)t(1;5)(q12;q21),+6,+8,+9,+10,+11,+12,+14,+14,+17,+18,+21,+21,+22
18	F/22	ALL	46,XX,t(1;5)(q21;q32)/42-48,idem,+8/48,idem,+der(5)t(1;5),+21
		Multiple myeloma
19	M	MM	50,X,-Y,del(1)(p22p31),+3,+der(5)t(1;5)(q12;q35),+7,+9,del(11)(p11p12),add(12)(p13),-13,-14,+15,+19,-22,+2mar/49,idem,-5
20	M	MM	59,X,del(Y)(q12),-X,-1,t(1;8)(q31;q24),-2,der(2)t(1;2)(q12;q32),-4,der(5)t(1;5)(q13;q34), dic(6;12)(q11;p12),-7,-8,-10,del(11)(p12p14),-12,-13,-13,-14,-16,add(16)(p12),dic(17;?)(q25;?),-20,+21,+21,-22,+2mar
21	F/51	MM	45,XX,del(1)(p22p32),der(5)t(1;5)(q25;q35),-10,t(11;14)(q13;q32),ins(13;12)(p11;q22q24),del(14)(q22)
22	F/74	MM M	44,X,-X,-1,inv(2)(p13q37),der(5)t(1;5)(q21;q35),der(6)t(1;6)(q21;q21),+del(11)(q21),-13,-14,der(17)(1;17)(p31;p13),+18,-20
23	F/39	MM	50,X,-X,+add(3)(q27),-4,+der(5)t(1;5)(q21;q35),+add(6)(q27),+del(7)(q32),t(8;22)(q24;q11),del(13)(q12q21),add(14)(q32),+15,+19
24	F/43	MM M	46,XX,add(1)(p22),del(3)(p24),-5,der(5)t(1;5)(q13;q31),-8,-14,add(17)(p13),add(19)(p13),+1-4mar
25	F	MM	42,X,-X,del(1)(p13p32),der(2)t(1;2)(q21;q25),del(4)(q31),t(8;13)(q24;q11),del(12)(p11),-13,-21/42,idem,der(5)t(1;5)(q21;q35),add(15)(p13),add(19)(q13)
26	F	MM	44,XX,+del(3)(q21q25),der(5)t(1;5)(q21;q35),der(8;14)(q10;q10),+der(8;14)(q10;q10),der(12;15)(q10;q10),-13,del(14)(q22q32),-22
27	M	MM	52-54,XY,der(1)t(1;8)(q21;q11)ins(1;?)(q21;?),add(1)(p22),der(2)t(2;8)(q37;q13),+5,+5,der(5)t(1;5)(q21;q22)x2,+7,der(7)del(7)(p12p13)t(1;7)(p?22;q36),+8,del(8)(p11),+9,t(9;12)(p10;p10),+11,+15,?t(16;22)(p12;q13),der(19)t(17;19)(q11;p13),+21,+22/55-56,idem,+7,+del(8)(p11),+12
28	M	MM	41-42,Y,der(X)t(X;1)(p22;q12),del(1)(p11p22),t(1;3)(p13;p25),-2,del(2)(q?33),-4,der(5)t(1;5)(q12;q35),t(6;22)(p12;p11),del(12)(p12p12),-13,add(17)(p11),-20/39-42,idem,-del(1),+der(1)del(1)(p11p22)t(1;11)(q?44;q12)ins(1;?)(q?21;?),ins(?11;?)(q12;?)
29	M	MM	82-92,XXY,-Y,-1,-1,der(1)add(1)(p36)add(1)(q42),-2,-2,del(3)(q21)x2,-4,-4,add(5)(q15),der(5)t(1;5)(q12;q15),add(6)(q21)x2,+7,+7,+7,add(7)(p22),add(7)(q36),der(7)t(1;7)(q12;q32)x3,+8,der(8)t(1;8)(q12;q22)x2,+9,+9,add(9)(p24),der(9)t(1;9)(q12;q34),der(10)t(1;10)(q12;q26),add(11)(p15)x2,-12,-13,del(?13)(q12q22)x3,-14,der(14)t(1;14)(p11;q32)x3,-15,-15,add(15)(p11),add(16)(q24),-17,add(17)(p11)x2,+19,+19,-20,+21,add(21)(p11),+22,add(22)(q13),inc
		Other malignancies
30	F/56	DLBCL LN	52,XX,add(1)(q32),add(3)(q29),+der(5)t(1;5)(q23;q13),del(7)(p13),del(11)(q21),t(11;14)(q22;q32),+add(18)(q23),+4mar
31	F/69	PTCL LN	101-107,XX,der(X;6)(p10;p10)x2,del(2)(p22),t(2;3)(q35;q29),der(3)t(3;22)(p22;q12)x3,+del(4)(q25q34),del(5)(q22q24)x2,+der(5)t(1;5)(q22;q13),+dup(6)(p2?1p12),+7,+der(7)t(7;7)(q21;p12),+add(9)(q21)x2,der(9)t(4;9)(q34;q21)x2,der(9;20)(p10;p10)x2,-10,-10,+ins(11;?)(q12;?),t(11;14)(p13;q11),+12,del(13)(q14q31)x2,del(14)(q21q31),+21,+21,+der(22)t(18;22)(q12;q12)x2,+mar
32	M/28	HTCL LN	46,XY,del(1)(q25),der(5)t(1;5)(q25;q31),der(9)t(9;13)(p23-24;?q14),del(13)(q12)
33	F/65	DLBCL LN	69-87,XXX,+1,del(1)(q22)x2,-4,+der(5)t(1;5)(q22;q15),-6,+7,+9,+11,+12,+13,t(14;18)(q32;q21)x2,+15,+16,+16,+17,-18,+19,+19,+19,+20,-22,+2-5mar
34	F/94	MF/SS T-lineage LN	44-45,XX,der(2)t(2;12)(p25;q11),der(5)t(1;5)(q25;q35),-9,-10,-13,der(14)t(6;14)(p21;p11),der(15)t(8;15)(q?;q26),der(17)t(13;17)(q?;q25),i(17)(q10),add(20)(q13),+21/44-45,XX,der(2)t(2;12),der(3)ins(3;3)(p26;q22q29)t(1;3)(q32;q22),del(5)(q13),+der(8)t(4;8)(q25;q21) t(4;8)(q35;p21),-9,-10,der(14)t(6;14),-15,-17,i(17)(q10),+21
35	F/72	MBCN	49,XX,-1,der(2)t(2;11)(q21;q21-22),+5,+der(5)t(1;5)(q21;q31),del(6)(q13q15),-8,add(14)(q32),+18,+der(?)t(?;12)(?;q21)x2
36	M/41	FL
37	F/43	FL LN	47,XX,t(1;16)(p34;q24),ins(2;?)(p13;?),+der(5)t(1;5)(q24;q33),ins(7;?)(q22;?),ins(12;?)(q15;?)
38	M	DLBCL LN	46,XY,der(1)t(1;13)(q32;q14),t(3;14)(q27;q32),der(5)t(1;5)(q25;q13),der(6)(1;6)(q25;q21),del(7)(q22q32),add(8)(p21),del(8)(q22),inv(9)(p13q13),der(13)t(8;13)(q22;q12)
39	M	DLBCL LN	54,XY,+X,+2,t(3;14)(q27;q32),+der(5)t(1;5)(q21;q13)x2,+del(6)(q12q27),+7,+11,+12,+add(17)(q21)
40	F	FL LN	47,XX,t(1;16)(p34;q24),ins(2;?)(p13;?),+der(5)t(1;5)(q24;q33),ins(7;?)(q22;?),ins(12;?)q15;?)

1. Dastugue et al., 1986; 2. Gyger et al., 1989; 3. Furuya et al., 1992; 4. Shikano et al., 1993; 5. Wong et al., 1993; 6. Johansson et al., 1997; 7. Borkhardt et al., 2000; 8. Van Limbergen et al., 2002; 9. Jekarl et al., 2010; 10. Quentin et al., 2011; 11. Saikevych et al., 1991; 12. Martin et al., 1996; 13. Rieder et al., 1996; 14. van den Berghe et al., 2000; 15. Chang et al., 2006; 16. Wehrli et al., 2009; 17. Paulsson et al ., 2015; 18. Safavi et al., 2015; 19. Smadja et al., 2001; 20. Smadja et al., 2003. 21. Nilsson et al., 2002; 22-24. Mohamed et al., 2007; 25-26. Lim et al., 2013; 27-29. Sawyer et al., 2014; 30. Jonveaux et al., 1990; 31. Schlegelberger et al., 1994; 32. Ott et al.,1998; 33. Jerkeman et al., 1999; 34. Perez-Vila et al., 2000; 35. Tanaka et al., 2001; 36. Le Baccon et al., 2001; 37. Horsman et al., 2003; 38.Yoshioka et al., 2005; 39. Ruminy et al., 2006; 40. Johnson et al., 2008.

M., male; F., female; CML., chronic myeloid leukemia; AML-M1., acute myeloblastic leukemia without maturation; MDS., myelodysplastic syndrome; AML-M0., acute myeloblastic leukemia with minimal differentiation; AML., acute myeloid leukemia; AML-M2., acute myeloblastic leukemia with maturation; BAL., bilineage or biphenotypic leukemia; ALL., acute lymphoblastic leukemia; MM., multiple myeloma; DLBCL., diffuse large B-cell lymphoma; LN., lymph node; PTCL., peripheral T-cell lymphoma ; HTCL., hepatosplenic T-cell lymphoma; MF/SS., mycosis fungoides/Sezary syndrome; MBCN., mature B-cell neoplasm; FL., follicular lymphoma.

Epidemiology

At least 40 reported cases; balanced sex ratio (22M/18F aged 0 to 76 years). Male prevalence in myeloid (7M/3F, aged 0 to 76 years) and ALL cases (6M/2F, aged 2 to 70 years). There were 5 males and 6 female MM patients (aged 39 to 73 years) and 4M/7F cases in other malignancies group (aged 28 to 90 years) (Table 1).

Prognosis

The prognosis is likely unfavorable in association with poor-risk genetic features and complex karyotypes.

Cytogenetics

Cytogenetics morphological

Unbalanced translocation, characterized by the presence of 2 copies of normal chromosome 1, only 1 copy of normal chromosome 5 and a derivative chromosome 5, containing 1q. Presents as 2 normal chromosomes 1 and 5 and a +der(5)t(1;5) chromosome in 14 out of 40 cases. The breakpoints in 1q varied from 1q12 to q25 and were located on 5q13-q35.

Additional anomalies

Appears as a sole chromosomal abnormality in 2 MDS patients: in a 5-years old boy with Fanconi anemia (Quentin et al., 2011) and in a 64-years old male who received therapy for Hodgkin disease (Johansson et al., 1997). Found in association with t(9;22) in a CML (Dastugue et al., 1986) and in 2 ALL cases (Saikevych et al., 1991; Rieder et al., 1996). Presents as a sole structural abnormality in association with numerical anomalies in 5 out of 8 ALL cases (Martin et al., 1996; van den Berghe et al., 2000; Chang et al., 2006; Paulsson et al ., 2015; Safavi et al., 2015) and complex karyotypes in the remaining patients. Associated with additional unbalanced chromosome 1q abnormalities in 3 myeloid (Furuya et al., 1992; Shikano et al., 1993; Van Limbergen et al., 2002), 1 ALL (Saikevych et al., 1991), 6 MM (Smadja et al., 2003; Mohamed et al., 2007; Lim et al., 2013; Sawyer et al., 2014) and 2 lymphoma patients (Le Baccon et al., 2001; Yoshioka et al., 2005).

Genes Involved and Proteins

Note

The balanced t(1;5)(q21;q33) results in TPM3 / PDGFRB and the t(1;5)(q23;q33) in PDE4DIP /PDGFRB fusion that are sensitive to inhibition with imatinib (Wilkinson et al., 2003; Rosati et al., 2006; Cheah et al., 2014) in chronic myeloproliferative disorders

Result of the Chromosomal Anomaly

Oncogenesis

Unbalanced translocations between 1q and 5q are chromosomal abnormalities detectable in a broad spectrum of haematological malignancies including both lymphoid and myeloid neoplasms. Although cytogenetically heterogeneous, the main consequence of this rearrangement is a genomic imbalance resulting from gain of genes on 1q associated with partial 5q monosomy. Trisomies of genes located on the long arm of chromosome 1 are likely be implicated in neoplastic processes by a gene dosage effect resulting in overexpression of several genes. Alternatively, effects of the concomitant partial aneuploidy of genes on the partner chromosome 5 may play a role. Deletion of genes located on the long arm of chromosome 5 is a well-known chromosomal abnormality in myeloproliferative malignancies, therefore loss of the genes from 5q may be involved in neoplastic transformation and/or disease progression in these disorders. Although der(5)t(1;5)(q12-q25;q13-q35) was found as the sole abnormality in 2 patients, it usually presents with primary abnormalities such as t(9;22), 5q-, trisomy 8, monosomy 7 in myeloid malignancies, hyperploidy in ALL, complex karyotypes in MM and lymphomas, therefore it is apparently a secondary event preceding or accompanying disease evolution. The observation of this anomaly in highly complex karyotypes may be predictive of unfavorable prognosis in hematologic malignancies.

Bibliography

Pubmed ID	Last Year	Title	Authors
10908648	2000	The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q.	Borkhardt A et al
16849281	2006	Cytogenetics in childhood acute lymphoblastic leukemia in Taiwan: a single-institutional experience.	Chang HH et al
24687085	2014	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.	Cheah CY et al
3489495	1986	t(14;14)(q11;q32) in biphenotypic blastic phase of chronic myeloid leukemia.	Dastugue N et al
2924886	1989	Translocation (1;5)(q23;q33) in adult acute non-lymphocytic leukemia.	Gyger M et al
12580956	2003	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes.	Horsman DE et al
20694842	2010	CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22).	Jekarl DW et al
10089896	1999	Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas.	Jerkeman M et al
9398862	1997	Translocations between the long arms of chromosomes 1 and 5 in hematologic malignancies are strongly associated with neoplasms of the myeloid lineages.	Johansson B et al
18720523	2008	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas.	Johnson NA et al
2253189	1990	Deletion of (7p13p14) in non-Hodgkin's lymphoma.	Jonveaux P et al
11579465	2001	Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma.	Le Baccon P et al
23673102	2013	Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.	Lim AS et al
8846121	1996	Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study.	Martin PL et al
17654686	2007	Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.	Mohamed AN et al
12225392	2002	Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation.	Nilsson T et al
9537480	1998	Abdominal T-cell non-Hodgkin's lymphoma of the gamma/delta type in a patient with selective immunoglobulin A deficiency.	Ott MM et al
10897140	2000	A new case of Sézary cell leukemia: a morphological variant of prolymphocytic leukemia.	Pérez-Vila Mf et al
25961940	2015	The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.	Paulsson K et al
21325596	2011	Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.	Quentin S et al
8982045	1996	Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia.	Rieder H et al
16838028	2006	TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia.	Rosati R et al
16619046	2006	Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology.	Ruminy P et al
25261097	2015	Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.	Safavi S et al
2033959	1991	Multiparameter analysis of acute mixed lineage leukemia: correlation of a B/myeloid immunophenotype and immunoglobulin and T-cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology.	Saikevych IA et al
24497533	2014	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.	Sawyer JR et al
7987800	1994	Recurrent chromosome abnormalities in peripheral T-cell lymphomas.	Schlegelberger B et al
8275449	1993	Jumping translocations of 1q in Burkitt lymphoma and acute nonlymphocytic leukemia.	Shikano T et al
11568011	2001	Hypodiploidy is a major prognostic factor in multiple myeloma.	Smadja NV et al
14506697	2003	Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.	Smadja NV et al
11165319	2001	Restricted chromosome breakpoint sites on 11q22-q23.1 and 11q25 in various hematological malignancies without MLL/ALL-1 gene rearrangement.	Tanaka K et al
11746988	2002	Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH.	Van Limbergen H et al
19167609	2009	Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.	Wehrli LA et al
12907457	2003	Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.	Wilkinson K et al
8342541	1993	Terminal acute myelogenous leukemia in a patient with congenital agranulocytosis.	Wong WY et al
15543600	2005	Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.	Yoshioka T et al
11156737	2000	Static cytometry identifies hyperdiploid childhood ALL.	van den Berghe JA et al

Summary

Class disease

NHL

Citation

Soad Al Bahar ; Adriana Zamecnikova

der(5)t(1;5)(q12-q25;q13-q35)

Atlas Genet Cytogenet Oncol Haematol. 2016-02-01

Online version: http://atlasgeneticsoncology.org/haematological/1646/der(5)t(1;5)(q12-q25;q13-q35)